Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MMP7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MMP7 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MMP7 Products |
| Gene Delivery | MMP7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MMP7 Products |
| Benchmark Ab | Anti-MMP7 (Sequence of Reference mAb) Recombinant positive control. |
View MMP7 Products |
| Validator | MMP7 siRNA Set For knockdown verification. |
View MMP7 Products |
| Related Target A | MMP9 Broad-spectrum selectivity counter-screening. |
View MMP9 Products |
| Related Target B | TIMP1 Natural physiological inhibitor of MMPs. |
View TIMP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MMP Family Homology / Off-Target Toxicity | Strictly sequence-verified homolog panel proteins (MMP1, 2, 7, 9) available with >95% purity for selectivity screening. |
| Complex Tertiary Structure Dependency | HEK293 Expressed (Native Glycosylation) to ensure proper folding of the catalytic domain. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks and target validation. |
Live MMP7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MMP7 therapeutics is intensifying, with major players shifting focus from traditional small molecule pan-MMP inhibitors (which historically failed due to musculoskeletal toxicities) to highly selective monoclonal antibodies and targeted delivery systems. As first-generation selective therapies enter the clinic, the next wave of R&D is targeting advanced fibrosis (like Idiopathic Pulmonary Fibrosis) and resistant solid tumors through antibody-drug conjugates (ADCs) and bispecific formats.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Gilead, Various Biotech | Oncology, Fibrosis | Selectivity Assay (Need High-Purity MMP Homolog Panel) |
| Peptide Inhibitors | Academic & Pharma Consortia | Colorectal Cancer | Enzymatic Activity Blockade (Need properly folded active MMP7) |
| ADC | Emerging Startups | Pancreatic/Gastric Tumors | Internalization Assay (Need high-purity ECD-Fc) |